Avenue Net Receivables from 2010 to 2024
| ATXI Stock | USD 2.06 0.02 0.98% |
Net Receivables | First Reported 2010-12-31 | Previous Quarter 81 K | Current Value 72 K | Quarterly Volatility 5 K |
Check Avenue Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avenue Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 165.9 K, Depreciation And Amortization of 15.3 M or Interest Expense of 350.7 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.13. Avenue financial statements analysis is a perfect complement when working with Avenue Therapeutics Valuation or Volatility modules.
Avenue | Net Receivables |
Currently Active Assets on Macroaxis
When determining whether Avenue Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Avenue Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Avenue Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Avenue Therapeutics Stock:Check out the analysis of Avenue Therapeutics Correlation against competitors. For more detail on how to invest in Avenue Stock please use our How to Invest in Avenue Therapeutics guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avenue Therapeutics. If investors know Avenue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avenue Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share 24.78 | Return On Assets (2.01) | Return On Equity (5.35) |
The market value of Avenue Therapeutics is measured differently than its book value, which is the value of Avenue that is recorded on the company's balance sheet. Investors also form their own opinion of Avenue Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Avenue Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avenue Therapeutics' market value can be influenced by many factors that don't directly affect Avenue Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avenue Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avenue Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avenue Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.